Evotec (EVO) is trading up at $1.66 (+3.75%), as of the latest quote. It operates in the Health Care sector.
Evotec revenue & net income history (FY2019–FY2024)
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | €446.4M | €500.9M | €618.0M | €751.4M | €781.4M | €797.0M |
| Growth (year over year) | — | +12.2% | +23.4% | +21.6% | +4.0% | +2.0% |
| Gross profit | €132.9M | €125.7M | €151.5M | €174.1M | €175.1M | €114.9M |
| Gross margin | 29.8% | 25.1% | 24.5% | 23.2% | 22.4% | 14.4% |
| Operating income | €62.7M | €48.6M | €41.0M | €20.9M | −€47.5M | −€142.5M |
| Operating margin | 14.0% | 9.7% | 6.6% | 2.8% | −6.1% | −17.9% |
| Net income | €38.2M | €6.28M | €215.5M | −€175.7M | −€83.9M | −€196.1M |
| Net margin | 8.5% | 1.3% | 34.9% | −23.4% | −10.7% | −24.6% |
| EPS (diluted) | €0.25 | €0.04 | €1.30 | −€0.99 | −€0.47 | −€1.11 |
| Balance sheet | ||||||
| Cash and equivalents | €277.0M | €422.6M | €699.3M | €415.2M | €510.9M | €306.4M |
| Total assets | — | €1.46B | €2.24B | €2.26B | €2.25B | €1.91B |
| Total liabilities | — | €737.9M | €857.5M | €1.07B | €1.13B | €960.0M |
| Shareholders' equity | €478.6M | €724.5M | €1.38B | €1.19B | €1.12B | €952.5M |
| Cash flow | ||||||
| Operating cash flow | €42.2M | €44.7M | €126.6M | €205.8M | €36.4M | €18.2M |
| Capital expenditure | €31.3M | €99.1M | €118.9M | €181.4M | €213.3M | €117.5M |
| Free cash flow | €10.9M | −€54.4M | €7.66M | €24.5M | −€176.9M | −€99.2M |
From Evotec's 20-F filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Euro (EUR), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
About Evotec
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
- Headquarters
- Hamburg, Germany From SEC filings, Oct 2026
Recent News
No recent news mentioning Evotec in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International